• Vaxart published an open letter urging shareholders to back its board ahead of the July 16, 2026 annual meeting, citing a proxy contest in which dissident investors nominated three directors.
• Management framed the next 12–18 months as a key inflection period for its oral vaccine platform, highlighting a fully enrolled BARDA-backed Phase 2b COVID-19 booster study with about 5,400 participants.
• 12-month safety data from the 400-person sentinel cohort is targeted for Q2 2026, with the primary efficacy and safety readout from the roughly 5,000-participant main cohort expected in early 2027.
• The letter pointed to about $61 million of cash resources at the end of Q1 2026, projecting funded runway into Q2 2027, citing cost cuts, a $25 million share purchase agreement, restored BARDA funding, and a Dynavax partnership later acquired by Sanofi.
• Shareholders were directed to https://vote.vaxart.com/ for additional information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-059127), on May 19, 2026, and is solely responsible for the information contained therein.